New Jersey A5534: Adult ADHD Telehealth Follow-Up Rule Change

Most health services owners in New Jersey don't realize that a provision buried in bill A5534 has already changed the rules for how often they must see adult patients on ADHD stimulant medications. The change cuts the mandatory follow-up frequency in half and eliminates the in-person requirement entirely—but only if you know it's there.

What Changed

Under previous New Jersey regulations, any health service prescribing Schedule II stimulants (such as Adderall or Ritalin) to adults for ADHD treatment was required to conduct in-person follow-up visits every 3 months. A5534 revises this requirement in Section 1, amending subsection e, paragraph (2).

The new rule: follow-up visits are now required only every 6 months, and those visits can be conducted via telehealth instead of in person. That means practices can cut the mandatory visit frequency by half and eliminate travel and scheduling barriers for patients.

Who This Affects

This change applies directly to:

• Telehealth and behavioral health practices prescribing stimulants to adult ADHD patients
• Primary care and specialty practices offering remote ADHD management
• Any licensed prescriber in New Jersey managing adult ADHD with Schedule II medications

If your practice currently schedules quarterly in-person visits for ADHD medication management, this provision affects your workflow, patient scheduling, and revenue cycle.

What It Means for Your Practice

The practical impact is significant. Practices that have been building quarterly in-person visit requirements into their ADHD protocols can now extend those intervals to six months and shift to telehealth. This reduces:

• Administrative burden of scheduling and documenting in-person visits
• No-show rates tied to in-person appointment barriers
• Overhead costs associated with clinic space and staff time for in-person visits

At the same time, practices must ensure documentation and clinical protocols reflect the new six-month interval and account for telehealth-based follow-ups. The change doesn't eliminate the follow-up requirement—it only changes the frequency and modality.

Timing and Implementation

A5534 became effective immediately upon enactment (Section 2), meaning the new six-month telehealth follow-up standard is already in force. Practices should review their current ADHD management protocols and patient schedules to ensure compliance with the updated requirement.

This is not optional. The provision is a regulatory change, not a guideline. Prescribers must follow the new six-month interval and can use telehealth for those visits.

Next Steps

Health services should audit current ADHD patient schedules and follow-up protocols to confirm alignment with the new six-month telehealth standard. If your practice is still requiring quarterly in-person visits, you may be operating under outdated requirements and should update your clinical and administrative workflows.

For a detailed, practice-specific summary of A5534 and other recent New Jersey telehealth regulatory changes, a free resource guide is available through the New Jersey Health Care Association and other trade organizations serving the state.